Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 bioRASI Comments on FDA Biosimilar Guidance | Contract Pharma

What are you searching for?

Sign in
Breaking News

bioRASI Comments on FDA Biosimilar Guidance

Provides input at public hearing

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

bioRASI has issued comments to the FDA in connection with the recent Draft Guidelines Relating to the Development of Biosimilar Products. “bioRASI is pleased that the FDA is making strides towards establishing a domestic approval pathway for these important drugs, which will provide patients with increased access to life saving medications,” said Boris Reznik Ph.D., chairman of bioRASI. “Just as the Hatch-Waxman Act facilitated the approval and marketing of lower cost but equally safe and effective small molecule drugs, the pending regulations and accompanying legislation will allow for the delivery of follow-on biologics to a greater population in the U.S. and abroad.”
 
“Many of our current clients are planning their expansion from generic drugs into the biosimilars market,” added Dr. Reznik. “As a powerful leader in generic drug development, bioRASI is leveraging our 10 years of biologics experience to advance these clients on their path to success.”
 
bioRASI has also commented on the three FDA issued guidance documents that were released in February 2012. The company participated in the public hearing regarding these documents on May 11th, and together with biopharmaceutical opinion-leaders, provided input on the draft guidelines. bioRASI’s comments related primarily to facilitating the approval pathway for biosimilars in various conditions of use, and for the demonstration of interchangeability as a path that can potentially be beneficial both for patients and for the biosimilars industry as a whole.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics